Angiodynamics Inc (ANGO) Stock Price, Quote & News

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy sy...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 518 795 1400

Website: www.angiodynamics.com

Address:

14 Plaza Drive, Latham, United States

joketrader Jul. 30 at 9:26 PM

$ANGO #tomorrow

0 · Reply

joketrader Jul. 29 at 6:14 PM

$ANGO Im swinging this

0 · Reply

joketrader Jul. 29 at 6:13 PM

$ANGO in for a swing 🤷🏽‍♂️

0 · Reply

joketrader Jul. 29 at 6:11 PM

$ANGO 👀 💪

0 · Reply

NVDAMillionaire Jul. 23 at 7:26 AM

$ANGO Outstanding article that hits the mark on ANGO's current state. So if you want to refresh your ANGO insights or learn about ANGO from scratch, this is a must read. https://beyondspx.com/article/angiodynamics-unlocking-medtech-growth-through-precision-and-strategic-focus-nasdaq-ango

0 · Reply

BioGem Jul. 19 at 11:05 AM

$ANGO I added sub $9. Many positives: -Excellent beat on top and bottom lines. Yes, the guidance for 2026 is average, but management has always been conservative as they progressively beat and raise. -Undervalued based on DCF and multiples. -All analysts kept or raised price targets up to $24. -High quality Execs and BOD. -High CEO ownership of stock: 7x base salary. -Re-structuring of Co since 2024 was achieved smoothly with strong balance sheet, all debt paid off. -Steady growth, high quality products and Nanoknife approved with inflection point. -Profits in sight and free cash flow positive. -Stock buy backs ++. $IBB $XBI

0 · Reply

d_risk Jul. 19 at 12:56 AM

$ANGO - AngioDynamics Inc. Common Stock - 10K - Updated Risk Factors ANGO’s 2025 risk factors pivot to market acceptance and reimbursement challenges, supply chain risks from trade tensions and partial outsourcing, intensified legal and regulatory scrutiny, restructuring impacts, worsening international sales decline, inflation and interest rate pressures, and ongoing EU regulatory hurdles; labor shortage and financing risks removed. #MedicalDevices #RegulatoryScrutiny #SupplyChainRisks #ReimbursementChallenges #MarketAcceptance 🟢 Added 🟠 Removed https://d-risk.ai/ANGO/10-K/2025-07-18

0 · Reply

Ka1ch123 Jul. 17 at 7:44 AM

$ANGO in @ 8.60. another runner?!

0 · Reply

JarvisFlow Jul. 16 at 6:49 PM

Lake Street has updated their rating for AngioDynamics ( $ANGO ) to Buy with a price target of 24.

0 · Reply

ZacksResearch Jul. 16 at 5:56 PM

$ANGO posts a narrower Q4 loss — but what's driving the optimism? 📈 ✔️ Adjusted loss per share beat estimates, trimming from last year ✔️ Revenues surged 12.9% in Q4, topping expectations ✔️ Strong Med Tech & Med Device performance led by Auryon and NanoKnife Discover the full earnings details here 👉 https://www.zacks.com/stock/news/2586115/ango-stock-down-despite-q4-earnings-beat-gross-margin-declines?cid=sm-stocktwits-2-2586115-body-2186&ADID=SYND_STOCKTWITS_TWEET_2_2586115_BODY_2186

0 · Reply

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

Jul 23, 2025, 8:30 AM EDT - 9 days ago

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

Jul 15, 2025, 12:40 PM EDT - 17 days ago

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

Jul 15, 2025, 11:59 AM EDT - 17 days ago

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

Jul 15, 2025, 6:30 AM EDT - 17 days ago

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Jul 7, 2025, 8:00 AM EDT - 25 days ago

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

Jun 23, 2025, 8:00 AM EDT - 5 weeks ago

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Apr 2, 2025, 10:41 AM EDT - 4 months ago

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

Apr 2, 2025, 10:20 AM EDT - 4 months ago

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

Apr 2, 2025, 6:30 AM EDT - 4 months ago

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

Mar 31, 2025, 8:00 AM EDT - 4 months ago

AngioDynamics to Host Virtual Cardiovascular Investor Event

Mar 19, 2025, 8:00 AM EDT - 4 months ago

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

Mar 10, 2025, 4:30 PM EDT - 5 months ago

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

Jan 30, 2025, 7:30 AM EST - 6 months ago

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

Jan 16, 2025, 5:07 AM EST - 7 months ago

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

Jan 13, 2025, 8:00 AM EST - 7 months ago

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Jan 8, 2025, 5:15 PM EST - 7 months ago

AngioDynamics: A Surgical Approach To Market Growth

Jan 8, 2025, 11:00 AM EST - 7 months ago

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

Jan 8, 2025, 6:30 AM EST - 7 months ago

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

Jan 6, 2025, 9:26 AM EST - 7 months ago

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:25 AM EST - 7 months ago

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

Dec 19, 2024, 5:00 PM EST - 8 months ago

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

Dec 9, 2024, 6:00 AM EST - 8 months ago

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

Oct 23, 2024, 8:00 AM EDT - 10 months ago

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

Oct 21, 2024, 8:00 AM EDT - 10 months ago

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

Oct 3, 2024, 10:29 AM EDT - 10 months ago

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

Oct 3, 2024, 10:02 AM EDT - 10 months ago

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

LEVI NGVT

Oct 3, 2024, 6:30 AM EDT - 10 months ago

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

Oct 3, 2024, 3:37 AM EDT - 10 months ago

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

Sep 19, 2024, 4:40 PM EDT - 11 months ago

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

Sep 19, 2024, 8:00 AM EDT - 11 months ago

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

Sep 3, 2024, 8:30 AM EDT - 11 months ago

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

Jul 29, 2024, 4:15 PM EDT - 1 year ago

AngioDynamics to Participate in Upcoming Investor Conferences

Jul 17, 2024, 3:16 PM EDT - 1 year ago

AngioDynamics: Lumpy Progress Is Still Progress

Jul 16, 2024, 1:51 PM EDT - 1 year ago

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

Jul 16, 2024, 10:35 AM EDT - 1 year ago

AngioDynamics (ANGO) Q4 2024 Earnings Call Transcript

Jul 16, 2024, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results

Jul 8, 2024, 4:30 PM EDT - 1 year ago

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

May 21, 2024, 5:30 PM EDT - 1 year ago

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System

May 6, 2024, 4:45 PM EDT - 1 year ago

AngioDynamics' APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

Apr 9, 2024, 4:49 PM EDT - 1 year ago

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

Apr 4, 2024, 11:11 AM EDT - 1 year ago

AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript

Apr 4, 2024, 7:00 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

Apr 4, 2024, 6:45 AM EDT - 1 year ago

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

Apr 1, 2024, 5:26 PM EDT - 1 year ago

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

Mar 19, 2024, 4:01 PM EDT - 1 year ago

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

Mar 6, 2024, 4:01 PM EST - 1 year ago

AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference

Feb 15, 2024, 4:05 PM EST - 1 year ago

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

Jan 23, 2024, 8:00 AM EST - 1 year ago

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

Jan 5, 2024, 10:26 AM EST - 1 year ago

AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript

joketrader Jul. 30 at 9:26 PM

$ANGO #tomorrow

0 · Reply

joketrader Jul. 29 at 6:14 PM

$ANGO Im swinging this

0 · Reply

joketrader Jul. 29 at 6:13 PM

$ANGO in for a swing 🤷🏽‍♂️

0 · Reply

joketrader Jul. 29 at 6:11 PM

$ANGO 👀 💪

0 · Reply

NVDAMillionaire Jul. 23 at 7:26 AM

0 · Reply

BioGem Jul. 19 at 11:05 AM

0 · Reply

d_risk Jul. 19 at 12:56 AM

0 · Reply

Ka1ch123 Jul. 17 at 7:44 AM

$ANGO in @ 8.60. another runner?!

0 · Reply

JarvisFlow Jul. 16 at 6:49 PM

Lake Street has updated their rating for AngioDynamics ( $ANGO ) to Buy with a price target of 24.

0 · Reply

ZacksResearch Jul. 16 at 5:56 PM

0 · Reply

drmha Jul. 16 at 5:25 PM

$ANGO the average price target is 16 I am very a ware if the company product portfolio One of its product the competitor is inari who was acquired by a deal equl 5 billion dollar This is for one product of ango only the competitor market cap. I am very confident-this company portfolio at least give her the value if 3- 5 billion dollar Its for me institutions manipulation

0 · Reply

ZacksResearch Jul. 16 at 4:15 PM

$ANGO beat Q4 — so why is the stock dropping? Strong Med Tech growth drove the earnings beat, but declining gross margins and a wider fiscal 2026 loss outlook are weighing heavy. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2586115/ango-stock-down-despite-q4-earnings-beat-gross-margin-declines?cid=sm-stocktwits-2-2586115-teaser-2144&ADID=SYND_STOCKTWITS_TWEET_2_2586115_TEASER_2144

0 · Reply

JarvisFlow Jul. 16 at 1:12 PM

HC Wainwright & Co. updates rating for AngioDynamics ( $ANGO ) to Buy, target set at 16.

0 · Reply

JarvisFlow Jul. 16 at 12:00 PM

Canaccord Genuity has adjusted their stance on AngioDynamics ( $ANGO ), setting the rating to Buy with a target price of 15 → 17.

0 · Reply

theflynews Jul. 15 at 8:24 PM

What You Missed On Wall Street On Tuesday - $ANGO - https://thefly.com/permalinks/entry.php/ANGOid4159991?1752610920C38

0 · Reply

SuperCoach Jul. 15 at 3:45 PM

$ANGO Time for Angio to hire a PROFESSIONAL who knows how to attract institutional buyers

0 · Reply

SuperCoach Jul. 15 at 3:44 PM

$ANGO We don’t need another positive quarter or more landmark breakthroughs. There’s no doubt in my mind that these will continue to happen. What we need is someone putting this investment opportunity in front of big investors.

1 · Reply

SuperCoach Jul. 15 at 3:43 PM

$ANGO Doesn’t matter how great a business or an investment opportunity is. If no one knows about it, then no one is gonna buy it.

0 · Reply

Hellrless Jul. 15 at 3:43 PM

$ANGO shit stock dump and short only way to make money on this shit thing you call “company”

0 · Reply

Hellrless Jul. 15 at 3:33 PM

$ANGO Holy fuck, this shit stock is worse than expected. Killed their earnings and went down what a piece of BS shit company

0 · Reply

drmha Jul. 15 at 3:07 PM

$ANGO this shit is a loser

0 · Reply

Freddoc Jul. 15 at 2:31 PM

$ANGO they could cure cancer and it would drop Time to look for a buyer to enhance shareholder value

0 · Reply

Market Cap	360.02M
Revenue (ttm)	292.50M
Net Income (ttm)	-33.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11.62%
Debt to Equity Ratio	0.00

Volume	371,100
Avg Vol	742,428
Day's Range	N/A - N/A
Shares Out	40.63M
Stochastic %K	5%
Beta	0.60
Analysts	Strong Sell
Price Target	$18.25